The Antibody Response against HIV-1.
暂无分享,去创建一个
[1] Jerome H. Kim,et al. Human immunodeficiency virus vaccine trials. , 2012, Cold Spring Harbor perspectives in medicine.
[2] N. Haigwood,et al. Lessons in nonhuman primate models for AIDS vaccine research: from minefields to milestones. , 2012, Cold Spring Harbor perspectives in medicine.
[3] J. Mascola,et al. Rational design of vaccines to elicit broadly neutralizing antibodies to HIV-1. , 2011, Cold Spring Harbor perspectives in medicine.
[4] E. Rosenberg,et al. Epitopes Immediately below the Base of the V3 Loop of gp120 as Targets for the Initial Autologous Neutralizing Antibody Response in Two HIV-1 Subtype B-Infected Individuals , 2011, Journal of Virology.
[5] C. Blish,et al. The Breadth and Potency of Passively Acquired Human Immunodeficiency Virus Type 1-Specific Neutralizing Antibodies Do Not Correlate with the Risk of Infant Infection , 2011, Journal of Virology.
[6] L. Morris,et al. The Neutralization Breadth of HIV-1 Develops Incrementally over Four Years and Is Associated with CD4+ T Cell Decline and High Viral Load during Acute Infection , 2011, Journal of Virology.
[7] Feng Gao,et al. Identification of amino acid substitutions associated with neutralization phenotype in the human immunodeficiency virus type-1 subtype C gp120. , 2011, Virology.
[8] B. Chohan,et al. HIV-1 superinfection and its implications for vaccine design. , 2010, Current HIV research.
[9] D. Montefiori,et al. Neutralization activity in a geographically diverse East London cohort of human immunodeficiency virus type 1-infected patients: clade C infection results in a stronger and broader humoral immune response than clade B infection. , 2010, The Journal of general virology.
[10] W. Weissenhorn,et al. Crystal Structure and Size-Dependent Neutralization Properties of HK20, a Human Monoclonal Antibody Binding to the Highly Conserved Heptad Repeat 1 of gp41 , 2010, PLoS pathogens.
[11] O. Pybus,et al. B-cell depletion reveals a role for antibodies in the control of chronic HIV-1 infection , 2010, Nature communications.
[12] M. Sagar. HIV-1 transmission biology: selection and characteristics of infecting viruses. , 2010, The Journal of infectious diseases.
[13] Mario Roederer,et al. Rational Design of Envelope Identifies Broadly Neutralizing Human Monoclonal Antibodies to HIV-1 , 2010, Science.
[14] C. Kankasa,et al. Functional properties of the HIV-1 subtype C envelope glycoprotein associated with mother-to-child transmission. , 2010, Virology.
[15] D. Venzon,et al. Multiple Vaccine-Elicited Nonneutralizing Antienvelope Antibody Activities Contribute to Protective Efficacy by Reducing both Acute and Chronic Viremia following Simian/Human Immunodeficiency Virus SHIV89.6P Challenge in Rhesus Macaques , 2010, Journal of Virology.
[16] E. Bunnik,et al. Cross-reactive neutralizing humoral immunity does not protect from HIV type 1 disease progression. , 2010, The Journal of infectious diseases.
[17] J. Kappes,et al. GP41-Specific Antibody Blocks Cell-Free HIV Type 1 Transcytosis through Human Rectal Mucosa and Model Colonic Epithelium , 2010, The Journal of Immunology.
[18] A MarioCalvo,et al. Vaccination with ALVAC and AIDS-VAX to prevent HIV-1 infection in Thailand , 2010 .
[19] J. Overbaugh,et al. Temporal analysis of HIV envelope sequence evolution and antibody escape in a subtype A-infected individual with a broad neutralizing antibody response. , 2010, Virology.
[20] Q. Sattentau,et al. Analysis of Memory B Cell Responses and Isolation of Novel Monoclonal Antibodies with Neutralizing Breadth from HIV-1-Infected Individuals , 2010, PloS one.
[21] Jerome H. Kim,et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. , 2009, The New England journal of medicine.
[22] Holly Janes,et al. Tiered Categorization of a Diverse Panel of HIV-1 Env Pseudoviruses for Assessment of Neutralizing Antibodies , 2009, Journal of Virology.
[23] Pham Phung,et al. Broad and Potent Neutralizing Antibodies from an African Donor Reveal a New HIV-1 Vaccine Target , 2009, Science.
[24] D. Dimitrov,et al. Germline-like predecessors of broadly neutralizing antibodies lack measurable binding to HIV-1 envelope glycoproteins: Implications for evasion of immune responses and design of vaccine immunogens , 2009, Biochemical and Biophysical Research Communications.
[25] L. Morris,et al. Specificity of the autologous neutralizing antibody response , 2009, Current opinion in HIV and AIDS.
[26] Lynn Morris,et al. Limited Neutralizing Antibody Specificities Drive Neutralization Escape in Early HIV-1 Subtype C Infection , 2009, PLoS pathogens.
[27] S. Gnanakaran,et al. Escape from Autologous Neutralizing Antibodies in Acute/Early Subtype C HIV-1 Infection Requires Multiple Pathways , 2009, PLoS pathogens.
[28] J. Binley. Specificities of broadly neutralizing anti-HIV-1 sera , 2009, Current opinion in HIV and AIDS.
[29] Lynn Morris,et al. Broad Neutralization of Human Immunodeficiency Virus Type 1 Mediated by Plasma Antibodies against the gp41 Membrane Proximal External Region , 2009, Journal of Virology.
[30] Pascal Poignard,et al. Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques , 2009, Nature Medicine.
[31] Lynn Morris,et al. Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine? , 2009, Nature Medicine.
[32] J. Baeten,et al. Breadth of Neutralizing Antibody Response to Human Immunodeficiency Virus Type 1 Is Affected by Factors Early in Infection but Does Not Influence Disease Progression , 2009, Journal of Virology.
[33] Lynn Morris,et al. Antibody Specificities Associated with Neutralization Breadth in Plasma from Human Immunodeficiency Virus Type 1 Subtype C-Infected Blood Donors , 2009, Journal of Virology.
[34] I. Wilson,et al. HIV-1 and influenza antibodies: seeing antigens in new ways , 2009, Nature Immunology.
[35] C. Blish,et al. Cross-Subtype Neutralization Sensitivity despite Monoclonal Antibody Resistance among Early Subtype A, C, and D Envelope Variants of Human Immunodeficiency Virus Type 1 , 2009, Journal of Virology.
[36] H. Liao,et al. Heterogeneous neutralizing antibody and antibody-dependent cell cytotoxicity responses in HIV-1 elite controllers , 2009, AIDS.
[37] Terri Wrin,et al. Human Immunodeficiency Virus Type 1 Elite Neutralizers: Individuals with Broad and Potent Neutralizing Activity Identified by Using a High-Throughput Neutralization Assay together with an Analytical Selection Algorithm , 2009, Journal of Virology.
[38] A. Moreau,et al. Maternal neutralizing antibodies against a CRF01_AE primary isolate are associated with a low rate of intrapartum HIV-1 transmission. , 2009, Virology.
[39] Richard T. Wyatt,et al. Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals , 2009, Nature.
[40] Susan Moir,et al. B cells in HIV infection and disease , 2009, Nature Reviews Immunology.
[41] D. Venzon,et al. Contribution of Nonneutralizing Vaccine-Elicited Antibody Activities to Improved Protective Efficacy in Rhesus Macaques Immunized with Tat/Env Compared with Multigenic Vaccines1 , 2009, The Journal of Immunology.
[42] S. Zolla-Pazner,et al. Preferential use of the VH5-51 gene segment by the human immune response to code for antibodies against the V3 domain of HIV-1. , 2009, Molecular immunology.
[43] E. Sandström,et al. Oral HIV-exposure elicits mucosal HIV-neutralizing antibodies in uninfected men who have sex with men , 2009, AIDS.
[44] John R. Mascola,et al. Analysis of Neutralization Specificities in Polyclonal Sera Derived from Human Immunodeficiency Virus Type 1-Infected Individuals , 2008, Journal of Virology.
[45] Xuesong Yu,et al. Factors Associated with the Development of Cross-Reactive Neutralizing Antibodies during Human Immunodeficiency Virus Type 1 Infection , 2008, Journal of Virology.
[46] F. Pereyra,et al. Continuous Viral Escape and Selection by Autologous Neutralizing Antibodies in Drug-Naïve Human Immunodeficiency Virus Controllers , 2008, Journal of Virology.
[47] D. Montefiori,et al. Correlation of Vaccine-Elicited Systemic and Mucosal Nonneutralizing Antibody Activities with Reduced Acute Viremia following Intrarectal Simian Immunodeficiency Virus SIVmac251 Challenge of Rhesus Macaques , 2008, Journal of Virology.
[48] J. Mascola,et al. Frequency and Phenotype of Human Immunodeficiency Virus Envelope-Specific B Cells from Patients with Broadly Cross-Neutralizing Antibodies , 2008, Journal of Virology.
[49] Vicki C. Ashley,et al. Initial B-Cell Responses to Transmitted Human Immunodeficiency Virus Type 1: Virion-Binding Immunoglobulin M (IgM) and IgG Antibodies Followed by Plasma Anti-gp41 Antibodies with Ineffective Control of Initial Viremia , 2008, Journal of Virology.
[50] B. Chohan,et al. Human Immunodeficiency Virus Type 1 Superinfection Occurs despite Relatively Robust Neutralizing Antibody Responses , 2008, Journal of Virology.
[51] Lynn Morris,et al. Profiling the Specificity of Neutralizing Antibodies in a Large Panel of Plasmas from Patients Chronically Infected with Human Immunodeficiency Virus Type 1 Subtypes B and C , 2008, Journal of Virology.
[52] R. Desrosiers,et al. Importance of the V1/V2 Loop Region of Simian-Human Immunodeficiency Virus Envelope Glycoprotein gp120 in Determining the Strain Specificity of the Neutralizing Antibody Response , 2008, Journal of Virology.
[53] S. Hammer,et al. HIV Vaccine Research: The Way Forward , 2008, Science.
[54] E. Sanders-Buell,et al. Cross-clade neutralization patterns among HIV-1 strains from the six major clades of the pandemic evaluated and compared in two different models. , 2008, Virology.
[55] Hanneke Schuitemaker,et al. Autologous Neutralizing Humoral Immunity and Evolution of the Viral Envelope in the Course of Subtype B Human Immunodeficiency Virus Type 1 Infection , 2008, Journal of Virology.
[56] Hui Li,et al. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection , 2008, Proceedings of the National Academy of Sciences.
[57] R. Kaul,et al. HIV-neutralizing immunoglobulin A and HIV-specific proliferation are independently associated with reduced HIV acquisition in Kenyan sex workers , 2008, AIDS.
[58] Terri Wrin,et al. Genetic and immunologic heterogeneity among persons who control HIV infection in the absence of therapy. , 2008, The Journal of infectious diseases.
[59] J. Sodroski,et al. The challenges of eliciting neutralizing antibodies to HIV-1 and to influenza virus , 2008, Nature Reviews Microbiology.
[60] G. Landucci,et al. FcγRIIa Genotype Predicts Progression of HIV Infection1 , 2007, The Journal of Immunology.
[61] A. Trkola,et al. In Vivo Efficacy of Human Immunodeficiency Virus Neutralizing Antibodies: Estimates for Protective Titers , 2007, Journal of Virology.
[62] D. Burton,et al. Fc receptor but not complement binding is important in antibody protection against HIV , 2007, Nature.
[63] P. Gilbert,et al. Recombinant gp120 Vaccine-Induced Antibodies Inhibit Clinical Strains of HIV-1 in the Presence of Fc Receptor-Bearing Effector Cells and Correlate Inversely with HIV Infection Rate1 , 2007, The Journal of Immunology.
[64] S Gnanakaran,et al. Clade-Specific Differences between Human Immunodeficiency Virus Type 1 Clades B and C: Diversity and Correlations in C3-V4 Regions of gp120 , 2007, Journal of Virology.
[65] Douglas D. Richman,et al. Dissecting the Neutralizing Antibody Specificities of Broadly Neutralizing Sera from Human Immunodeficiency Virus Type 1-Infected Donors , 2007, Journal of Virology.
[66] Hui Li,et al. Neutralizing Antibody Responses in Acute Human Immunodeficiency Virus Type 1 Subtype C Infection , 2007, Journal of Virology.
[67] Jun Li,et al. Antiviral Antibodies Are Necessary for Control of Simian Immunodeficiency Virus Replication , 2007, Journal of Virology.
[68] Tongqing Zhou,et al. Structural definition of a conserved neutralization epitope on HIV-1 gp120 , 2007, Nature.
[69] A. MacNeil,et al. Comparison of Heterologous Neutralizing Antibody Responses of Human Immunodeficiency Virus Type 1 (HIV-1)- and HIV-2-Infected Senegalese Patients: Distinct Patterns of Breadth and Magnitude Distinguish HIV-1 and HIV-2 Infections , 2007, Journal of Virology.
[70] D. Richman,et al. Lack of neutralizing antibody response to HIV-1 predisposes to superinfection. , 2006, Virology.
[71] F. Bibollet-Ruche,et al. Role of V1V2 and Other Human Immunodeficiency Virus Type 1 Envelope Domains in Resistance to Autologous Neutralization during Clade C Infection , 2007, Journal of Virology.
[72] A. Trkola,et al. Complement Lysis Activity in Autologous Plasma Is Associated with Lower Viral Loads during the Acute Phase of HIV-1 Infection , 2006, PLoS medicine.
[73] Feng Gao,et al. Genetic and Neutralization Properties of Subtype C Human Immunodeficiency Virus Type 1 Molecular env Clones from Acute and Early Heterosexually Acquired Infections in Southern Africa , 2006, Journal of Virology.
[74] Karina Yusim,et al. Role of Maternal Autologous Neutralizing Antibody in Selective Perinatal Transmission of Human Immunodeficiency Virus Type 1 Escape Variants , 2006, Journal of Virology.
[75] Christos J. Petropoulos,et al. Neutralizing Antibody Responses against Autologous and Heterologous Viruses in Acute versus Chronic Human Immunodeficiency Virus (HIV) Infection: Evidence for a Constraint on the Ability of HIV To Completely Evade Neutralizing Antibody Responses , 2006, Journal of Virology.
[76] S. Brunet,et al. Revisiting the role of neutralizing antibodies in mother-to-child transmission of HIV-1. , 2006, The Journal of infectious diseases.
[77] J. Overbaugh,et al. Diversity in HIV-1 envelope V1-V3 sequences early in infection reflects sequence diversity throughout the HIV-1 genome but does not predict the extent of sequence diversity during chronic infection. , 2006, AIDS research and human retroviruses.
[78] Thomas C. Quinn,et al. Neutralizing Antibodies Do Not Mediate Suppression of Human Immunodeficiency Virus Type 1 in Elite Suppressors or Selection of Plasma Virus Variants in Patients on Highly Active Antiretroviral Therapy , 2006, Journal of Virology.
[79] Barbra A. Richardson,et al. Neutralization Escape Variants of Human Immunodeficiency Virus Type 1 Are Transmitted from Mother to Infant , 2006, Journal of Virology.
[80] Yang Liu,et al. Neutralizing antibody responses drive the evolution of human immunodeficiency virus type 1 envelope during recent HIV infection. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[81] Bette Korber,et al. Structure of a V3-Containing HIV-1 gp120 Core , 2005, Science.
[82] Robyn L Stanfield,et al. Antibody vs. HIV in a clash of evolutionary titans. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[83] R. Ruprecht,et al. Antibodies: can they protect against HIV infection? , 2005, Current drug targets. Infectious disorders.
[84] Dorothy M. Lang,et al. Selection for Human Immunodeficiency Virus Type 1 Envelope Glycosylation Variants with Shorter V1-V2 Loop Sequences Occurs during Transmission of Certain Genetic Subtypes and May Impact Viral RNA Levels , 2005, Journal of Virology.
[85] Michael G Hudgens,et al. Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial. , 2005, The Journal of infectious diseases.
[86] D. Venzon,et al. Vaccine-Elicited Antibodies Mediate Antibody-Dependent Cellular Cytotoxicity Correlated with Significantly Reduced Acute Viremia in Rhesus Macaques Challenged with SIVmac2511 , 2005, The Journal of Immunology.
[87] S. Buchbinder,et al. Human Immunodeficiency Virus Type 1 (HIV-1) Diversity at Time of Infection Is Not Restricted to Certain Risk Groups or Specific HIV-1 Subtypes , 2004, Journal of Virology.
[88] Kimberly C. Brouwer,et al. Polymorphism of Fc receptor IIa for IgG in infants is associated with susceptibility to perinatal HIV-1 infection , 2004, AIDS.
[89] S. Zolla-Pazner,et al. The V1/V2 Domain of gp120 Is a Global Regulator of the Sensitivity of Primary Human Immunodeficiency Virus Type 1 Isolates to Neutralization by Antibodies Commonly Induced upon Infection , 2004, Journal of Virology.
[90] R. Doms,et al. HIV Transmission , 2004, The Journal of experimental medicine.
[91] Bette T. Korber,et al. Envelope-Constrained Neutralization-Sensitive HIV-1 After Heterosexual Transmission , 2004, Science.
[92] J. Baeten,et al. Identification of modifiable factors that affect the genetic diversity of the transmitted HIV-1 population , 2004, AIDS.
[93] Wayne A Hendrickson,et al. Structural basis of tyrosine sulfation and VH-gene usage in antibodies that recognize the HIV type 1 coreceptor-binding site on gp120. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[94] Martin A. Nowak,et al. Antibody neutralization and escape by HIV-1 , 2003, Nature.
[95] D. Richman,et al. Rapid evolution of the neutralizing antibody response to HIV type 1 infection , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[96] D. Montefiori,et al. Effect of Humoral Immune Responses on Controlling Viremia during Primary Infection of Rhesus Monkeys with Simian Immunodeficiency Virus , 2003, Journal of Virology.
[97] John P. Moore,et al. Nonneutralizing Antibodies to the CD4-Binding Site on the gp120 Subunit of Human Immunodeficiency Virus Type 1 Do Not Interfere with the Activity of a Neutralizing Antibody against the Same Site , 2003, Journal of Virology.
[98] J. Clements,et al. Sustained antibody-dependent cell-mediated cytotoxicity (ADCC) in SIV-infected macaques correlates with delayed progression to AIDS. , 2002, AIDS research and human retroviruses.
[99] D. Montefiori,et al. Regional Clustering of Shared Neutralization Determinants on Primary Isolates of Clade C Human Immunodeficiency Virus Type 1 from South Africa , 2002, Journal of Virology.
[100] C. Cheng‐Mayer,et al. Antibody Protects Macaques against Vaginal Challenge with a Pathogenic R5 Simian/Human Immunodeficiency Virus at Serum Levels Giving Complete Neutralization In Vitro , 2001, Journal of Virology.
[101] E. Daar,et al. Antibody from Patients with Acute Human Immunodeficiency Virus (HIV) Infection Inhibits Primary Strains of HIV Type 1 in the Presence of Natural-Killer Effector Cells , 2001, Journal of Virology.
[102] G. Landucci,et al. Relationship between antibody-dependent cellular cytotoxicity, plasma HIV type 1 RNA, and CD4+ lymphocyte count. , 2001, AIDS research and human retroviruses.
[103] L. Heyndrickx,et al. Identification and characterization of sera from HIV‐infected individuals with broad cross‐neutralizing activity against group M (env clade A–H) and group O primary HIV‐1 isolates , 2000, Journal of medical virology.
[104] J. Mascola,et al. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies , 2000, Nature Medicine.
[105] Tahir A. Rizvi,et al. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian–human immunodeficiency virus infection , 2000, Nature Medicine.
[106] L. Sánchez-Pulido,et al. Molecular analysis of HIV‐1 gp120 antibody response using isotype IgM and IgG phage display libraries from a long‐term non‐progressor HIV‐1‐infected individual , 1999, European journal of immunology.
[107] A Muñoz,et al. A longitudinal study of neutralizing antibodies and disease progression in HIV-1-infected subjects. , 1999, The Journal of infectious diseases.
[108] J. Mascola,et al. Protection of Macaques against Pathogenic Simian/Human Immunodeficiency Virus 89.6PD by Passive Transfer of Neutralizing Antibodies , 1999, Journal of Virology.
[109] N. Haigwood,et al. Neutralizing antibody directed against the HIV–1 envelope glycoprotein can completely block HIV–1/SIV chimeric virus infections of macaque monkeys , 1999, Nature Medicine.
[110] J. Mascola,et al. Correlation between humoral responses to human immunodeficiency virus type 1 envelope and disease progression in early-stage infection. , 1998, The Journal of infectious diseases.
[111] J. Goudsmit,et al. Neutralizing antibodies are positively associated with CD4+ T‐cell counts and T‐cell function in long‐term AIDS‐free infection , 1998, AIDS.
[112] D. Thea,et al. Neutralizing antibody and perinatal transmission of human immunodeficiency virus type 1. New York City Perinatal HIV Transmission Collaborative Study Group. , 1998, AIDS research and human retroviruses.
[113] E. Fenyö,et al. Augmented serum neutralizing activity against primary human immunodeficiency virus type 1 (HIV-1) isolates in two groups of HIV-1-infected long-term nonprogressors. , 1997, The Journal of infectious diseases.
[114] D. Neau,et al. Course of specific T lymphocyte cytotoxicity, plasma and cellular viral loads, and neutralizing antibody titers in 17 recently seroconverted HIV type 1-infected patients. , 1997, AIDS research and human retroviruses.
[115] D. Montefiori,et al. Neutralizing antibody responses to human immunodeficiency virus type 1 in primary infection and long-term-nonprogressive infection. , 1997, The Journal of infectious diseases.
[116] J. Overbaugh,et al. Specific N-linked and O-linked glycosylation modifications in the envelope V1 domain of simian immunodeficiency virus variants that evolve in the host alter recognition by neutralizing antibodies , 1997, Journal of virology.
[117] H. Fleury,et al. Autologous and heterologous neutralizing antibody responses following initial seroconversion in human immunodeficiency virus type 1-infected individuals , 1997, Journal of virology.
[118] H. Katinger,et al. The consequence of passive administration of an anti-human immunodeficiency virus type 1 neutralizing monoclonal antibody before challenge of chimpanzees with a primary virus isolate , 1996, Journal of virology.
[119] S. J. Clark,et al. HIV-specific cellular and humoral immune responses in primary HIV infection. , 1996, AIDS research and human retroviruses.
[120] B. Walker,et al. Strong cytotoxic T cell and weak neutralizing antibody responses in a subset of persons with stable nonprogressing HIV type 1 infection. , 1996, AIDS research and human retroviruses.
[121] A. Trkola,et al. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1 , 1996, Journal of virology.
[122] B. Korber,et al. Inter- and intraclade neutralization of human immunodeficiency virus type 1: genetic clades do not correspond to neutralization serotypes but partially correspond to gp120 antigenic serotypes , 1996, Journal of virology.
[123] B. Chohan,et al. Diversity in virus populations from genital secretions and peripheral blood from women recently infected with human immunodeficiency virus type 1 , 1995, Journal of virology.
[124] G. Berke. Unlocking the secrets of CTL and NK cells. , 1995, Immunology today.
[125] D. Venzon,et al. Vertical transmission of human immunodeficiency virus type 1: autologous neutralizing antibody, virus load, and virus phenotype. , 1995, The Journal of pediatrics.
[126] D. Ho,et al. Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection. , 1995, The New England journal of medicine.
[127] J. Levy,et al. Features of HIV-1 that could influence maternal-child transmission. , 1994, JAMA.
[128] J. Moore,et al. Development of the anti-gp120 antibody response during seroconversion to human immunodeficiency virus type 1 , 1994, Journal of virology.
[129] H Hengartner,et al. Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity. , 1994, Science.
[130] E. Halapi,et al. Neutralizing antibodies and viral characteristics in mother‐to‐child transmission of HIV‐1 , 1993, AIDS.
[131] D. Ho,et al. Genotypic and phenotypic characterization of HIV-1 patients with primary infection. , 1993, Science.
[132] J. Albert,et al. Mother-to-child transmission of human immunodeficiency virus type 1: correlation with neutralizing antibodies against primary isolates. , 1993, The Journal of infectious diseases.
[133] E. Holmes,et al. Selection for specific sequences in the external envelope protein of human immunodeficiency virus type 1 upon primary infection , 1993, Journal of virology.
[134] A. Saah,et al. Relationship of human immunodeficiency virus type 1 sequence heterogeneity to stage of disease. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[135] J. Overbaugh,et al. Alterations in potential sites for glycosylation predominate during evolution of the simian immunodeficiency virus envelope gene in macaques , 1992, Journal of virology.
[136] B. Korber,et al. Selective transmission of human immunodeficiency virus type-1 variants from mothers to infants. , 1992, Science.
[137] W. Schleif,et al. Prevention of HIV-1 infection in chimpanzees by gpl20 V3 domain-specific monoclonal antibody , 1992, Nature.
[138] J Overbaugh,et al. Variation in simian immunodeficiency virus env is confined to V1 and V4 during progression to simian AIDS , 1991, Journal of virology.
[139] K. Murthy,et al. Prevention of HIV infection by passive immunization with HIV immunoglobulin. , 1991, AIDS research and human retroviruses.
[140] P. Johnson,et al. The genetic fate of molecularly cloned simian immunodeficiency virus in experimentally infected macaques. , 1991, Virology.
[141] R. Desrosiers,et al. Selection of genetic variants of simian immunodeficiency virus in persistently infected rhesus monkeys , 1991, Journal of virology.
[142] R. Herberman,et al. Lymphocyte-mediated cytotoxicity. , 1987, Pediatric annals.
[143] J. Baeten,et al. HIV-1 neutralizing antibody breadth is affected by factors early in infection, but does not influence disease progression. Journal of Virology 83(10):10269-74 , 2009 .
[144] G. Landucci,et al. FcgammaRIIa genotype predicts progression of HIV infection. , 2007, Journal of immunology.
[145] J. Overbaugh,et al. Gender differences in HIV-1 diversity at time of infection , 2000, Nature Medicine.
[146] J. Levy,et al. Virological and immunological features of long-term human immunodeficiency virus-infected individuals who have remained asymptomatic compared with those who have progressed to acquired immunodeficiency syndrome. , 1998, Blood.
[147] D. Montefiori,et al. Neutralizing and infection-enhancing antibody responses to human immunodeficiency virus type 1 in long-term nonprogressors. , 1996, The Journal of infectious diseases.